Stay updated with breaking news from Aipsc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Shares of Century Therapeutics, Inc. (NASDAQ:IPSC – Get Free Report) have been assigned an average recommendation of “Moderate Buy” from the eight ratings firms that are covering the firm, MarketBeat reports. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company. The average 12 […]
Century Therapeutics, Inc. (NASDAQ:IPSC – Get Free Report) has been given an average rating of “Moderate Buy” by the eight ratings firms that are covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating on the company. The average twelve-month […]
Century Therapeutics, Inc. (NASDAQ:IPSC – Get Free Report) has been given an average rating of “Moderate Buy” by the eight research firms that are presently covering the stock, Marketbeat reports. One analyst has rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average 12-month price objective […]
.jpg)
Discover how to improve the efficiency and success of iPSC cloning, while decreasing time, expense, and effort.
Gladius Capital Management LP purchased a new position in Century Therapeutics, Inc. (NASDAQ:IPSC – Free Report) during the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 7,730 shares of the company’s stock, valued at approximately $27,000. A number of other institutional investors and hedge […]